LOGIN  |  REGISTER
Astria Therapeutics
Chimerix

Agilent Technologies to Participate in Citi’s 2025 Global Healthcare Conference

November 18, 2025 | Last Trade: US$157.20 3.60 2.34

SANTA CLARA, Calif. / Nov 18, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that Chief Enterprise Transformation Officer Tom Callihan and Head of Investor Relations Tejas Savant will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference. The event is scheduled for 9 to 9:45 a.m. EDT on Thursday, Dec. 4, 2025, in Miami, Florida.

A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom. Follow Agilent on LinkedIn and Facebook.

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page